Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03934814 · ClinicalTrials.gov registry record · Phase 1
Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma
A Phase 1 study, sponsored by I-Mab Biopharma US Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 98
- Enrollment target
NCT03934814: Completed Phase 1 study, sponsored by I-Mab Biopharma US Limited.
NCT03934814 is a Phase 1 study that has completed, run by I-Mab Biopharma US Limited. The registered enrollment target is 98 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (63% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03934814, a Phase 1 study, has completed, sponsored by I-Mab Biopharma US Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 98 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and tolerability of TJ011133 in participants with solid tumors and lymphoma.
Primary Outcome
Part 1A DLT period is 3 weeks, Part 1B DLT period is 3 weeks, Part 1C DLT period is 4 weeks.
Interventions
- DRUG Pembrolizumab
- DRUG Rituximab
- DRUG TJ011133
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2019-04-16 |
| Est. Completion | 2023-01-10 |
| Phase | Phase 1 |
What the finished NCT03934814 record still lists
NCT03934814 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 98 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (63% higher).
The record links to 0 conditions, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT03934814 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03934814 about?
NCT03934814 is a clinical study titled "Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma". The purpose of this study is to assess the safety and tolerability of TJ011133 in participants with solid tumors and lymphoma.
What is the current status of trial NCT03934814?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 98 participants. The study started on 2019-04-16. Estimated completion is 2023-01-10.
What interventions are being tested in trial NCT03934814?
The interventions under investigation include: Pembrolizumab (DRUG), Rituximab (DRUG), TJ011133 (DRUG).
Who is sponsoring clinical trial NCT03934814?
This trial is sponsored by I-Mab Biopharma US Limited, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03934814's enrollment target sits among peer trials
98 592nd of 2000 higher than 1,404 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02926729 · 98 participants · NA
Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy
- NCT03382977 · 98 participants · Phase 1
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
- NCT04577014 · 98 participants · Phase 1
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
- NCT04817618 · 98 participants · Phase 3
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI